Literature DB >> 15980151

Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.

Sumathi Sankaran1, Moraima Guadalupe, Elizabeth Reay, Michael D George, Jason Flamm, Thomas Prindiville, Satya Dandekar.   

Abstract

Limited information is available on the molecular mechanisms by which long-term HIV-1-infected nonprogressors suppress HIV-1 infection and maintain immune functions. The intestinal mucosal immune system is an early target for HIV-1 infection and severe CD4+ T cell depletion. We evaluated mucosal T lymphocyte subsets, virus-specific cellular responses, gene expression profiles, and viral loads in intestinal mucosal biopsies of long-term nonprogressor (LTNP) patients as compared to chronically HIV-1-infected patients with high viral loads (HVLs) and CD4+ T cell loss, as well as HIV-seronegative healthy individuals. This study aims to identify the mucosal correlates of HIV disease progression and to determine the molecular changes associated with immune and intestinal dysfunction. LTNP patients had undetectable viral loads, normal CD4+ T cell levels, and virus-specific cellular responses in peripheral blood and mucosal compartments. Microarray analysis revealed a significant increase in gene expression regulating immune activation, cell trafficking, and inflammatory response in intestinal mucosa of HVL patients as compared to LTNP patients. Genes associated with cell cycle regulation, lipid metabolism, and epithelial cell barrier and digestive functions were down-regulated in both HVL and LTNP patients. This may adversely influence nutrient adsorption and digestive functions, with the potential to impact the efficacy of antiretroviral therapy. We demonstrate that the maintenance of mucosal T cells, virus-specific responses, and distinct gene expression profiles correlate with clinical outcome in LTNP patients. However, the intestinal mucosal immune system remains an important target of HIV-1 infection in LTNP, and these effects may ultimately contribute toward disease progression.

Entities:  

Mesh:

Year:  2005        PMID: 15980151      PMCID: PMC1159164          DOI: 10.1073/pnas.0503463102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.

Authors:  K V Komanduri; M N Viswanathan; E D Wieder; D K Schmidt; B M Bredt; M A Jacobson; J M McCune
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

2.  Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays.

Authors:  G K Geiss; R E Bumgarner; M C An; M B Agy; A B van 't Wout; E Hammersmark; V S Carter; D Upchurch; J I Mullins; M G Katze
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines.

Authors:  J Olsson; M Poles; A L Spetz; J Elliott; L Hultin; J Giorgi; J Andersson; P Anton
Journal:  J Infect Dis       Date:  2000-10-23       Impact factor: 5.226

4.  Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals.

Authors:  Kazushi Motomura; Nobuaki Toyoda; Kazunori Oishi; Hironori Sato; Shigenori Nagai; Shin-ichi Hashimoto; Sitefano Buguruka Tugume; Richard Enzama; Roy Mugewa; Cissy Kityo Mutuluuza; Peter Mugyeyi; Tsuyoshi Nagatake; Kouji Matsushima
Journal:  Int Immunopharmacol       Date:  2004-12-20       Impact factor: 4.932

5.  Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.

Authors:  Michael D George; Elizabeth Reay; Sumathi Sankaran; Satya Dandekar
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques.

Authors:  J D Stone; C C Heise; C J Miller; C H Halsted; S Dandekar
Journal:  AIDS       Date:  1994-09       Impact factor: 4.177

7.  Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction.

Authors:  C Heise; C J Miller; A Lackner; S Dandekar
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

Review 8.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.

Authors:  V J Wacher; J A Silverman; Y Zhang; L Z Benet
Journal:  J Pharm Sci       Date:  1998-11       Impact factor: 3.534

9.  Simian immunodeficiency virus infection of the gastrointestinal tract of rhesus macaques. Functional, pathological, and morphological changes.

Authors:  C Heise; P Vogel; C J Miller; C H Halsted; S Dandekar
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

10.  Quantitative real-time PCR for the measurement of feline cytokine mRNA.

Authors:  C M Leutenegger; C N Mislin; B Sigrist; M U Ehrengruber; R Hofmann-Lehmann; H Lutz
Journal:  Vet Immunol Immunopathol       Date:  1999-11-30       Impact factor: 2.046

View more
  75 in total

Review 1.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

2.  Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease.

Authors:  Sumathi Sankaran-Walters; Kanat Ransibrahmanakul; Irina Grishina; Jason Hung; Enrique Martinez; Thomas Prindiville; Satya Dandekar
Journal:  J Clin Virol       Date:  2010-10-28       Impact factor: 3.168

Review 3.  Pathogenesis of HIV in the gastrointestinal tract.

Authors:  Satya Dandekar
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 4.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

5.  Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Authors:  Moraima Guadalupe; Sumathi Sankaran; Michael D George; Elizabeth Reay; David Verhoeven; Barbara L Shacklett; Jason Flamm; Jacob Wegelin; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 7.  Old world monkeys and new age science: the evolution of nonhuman primate systems virology.

Authors:  Robert E Palermo; Jennifer Tisoncik-Go; Marcus J Korth; Michael G Katze
Journal:  ILAR J       Date:  2013

Review 8.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

9.  Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.

Authors:  Sumathi Sankaran; Michael D George; Elizabeth Reay; Moraima Guadalupe; Jason Flamm; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.

Authors:  A Anselmi; D Vendrame; O Rampon; C Giaquinto; M Zanchetta; A De Rossi
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.